Athira Pharma is a biotechnology and pharmaceutical company headquartered in the United States, founded in 2011. The company's slogan, "Restoring lives by advancing bold therapies for neuronal health, thoughtfully and urgently," reflects its mission to restore neuronal health for those suffering from neurological diseases such as Alzheimer’s, Parkinson’s disease dementia, and dementia with Lewy bodies. Athira Pharma's latest milestone includes a $103.50M post-IPO equity investment on 20 January 2021, signaling confidence in the company's approach. The company is driven by a motivated, impassioned team committed to making a positive impact on human health.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Equity | $103.50M | - | 20 Jan 2021 | |
Grant | $15.00M | 1 | National Institute on Aging | 08 Dec 2020 |
Convertible Note | Unknown | 1 | 04 Sep 2020 | |
Series B | $85.00M | 10 | Suzanne Kayne, Surveyor Capital +1 | 04 Jun 2020 |
Series B | $15.20M | 7 | Michael Montgomery, Kayne Anderson Capital Advisors +2 | 02 Nov 2017 |
No recent news or press coverage available for Athira Pharma.